ABT

Abbott Laboratories (ABT) | Rumor.io

Abbott Laboratories

ABT

Attention (50-day avg)0%

Attention rank (50-day avg)#775

Bullish sentiment (50-day avg)95%

Price to earnings ratio32.7

Market capitalization174.7B

Earnings per share3.09

Dividend yield (TTM)2.33%

Revenue (annual)44.3B

Net income (annual)6.5B

Social

What share of all stock conversation is about ABT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.03	0.01% +0.01	0.01% +0	0.01% -0.03

Sep 13

Abbott Laboratories (ABT) was among a list of 39 dividend stocks that passed four basic safety rules, including a 55% payout test, out of 134 filtered stocks.
Gov. Abbott of Texas has cracked down on data centers, requiring them to produce their own electricity and not pass costs to residential customers, citing concerns about past electricity outages in the state.
Abbott Laboratories is mentioned as a potential investment consideration, along with BYD, in a comment about buying stocks.

Generated by AI

Sentiment

Of the messages about ABT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +30.65	95.24% +5.04	84.07% -3.24
Bearish	—	0% -30.65	4.76% -5.04	15.93% +3.24

Bullish· Jul 16

Abbott Laboratories ($ABT) is expected to rally back above $100 in coming weeks, driven by a solid quarter with a medtech business inflection and more beat-and-raise quarters ahead.
The company's Q2 beat and raised guidance have led to a significant price increase, with $ABT up 11% on heavy volume, and the stock is expected to continue its upward momentum.
Analysts are optimistic about Abbott's prospects, with the company raising its FY26 adjusted EPS view to $5.45-$5.60, and projecting full-year 2026 comparable sales growth of 6.5% to 7.5%, exceeding consensus estimates.

Bearish· May 8

Abbott Laboratories is experiencing a decline in stock price, with some investors expecting it to hit $80 or for the market to shift away from the chip sector.
The company's lawsuits are a major concern, with some investors believing that relief will only come once they expire.
The stock's recent performance has been seen as a "classic fail" and a "value trap" by some investors, with some even calling it "cancerous" and "retarded".

Generated by AI

Topics

Of the messages about ABT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	60%	3.13%	13.52%	28.32%
Technical Analysis	0%	71.79%	61.14%	6.12%
Announcements	20%	22.57%	17.33%	17.6%
Earnings	0%	0%	0%	6.02%
Analysts	0%	2.19%	7.81%	30.1%
Controversies	20%	0.31%	0.19%	11.84%

Earnings· Apr 16

Abbott Laboratories reported Q1 earnings of $1.15 per share, beating the FactSet Consensus of $1.14, and revenue of $11.16B, a 7.8% increase year-over-year.
The company cut its adjusted earnings per share guidance for FY26 to $5.38-$5.58, below consensus estimates, citing acquisition costs and margin pressure.
Abbott Laboratories' shares fell ~4% despite the earnings beat, as investors pointed to the acquisition of Exact Sciences as a drag on the company's performance and pressure on earnings.

Analysts· Jan 27

Morgan Stanley lowered its price target for Abbott Laboratories ($ABT) to $151.00 from $157.00.
Raymond James analysts maintain an Outperform rating for Abbott Laboratories ($ABT) with a lowered price target of $143.00.
Analysts at UBS Group and Credit Suisse Group have raised their price targets for Abbott Laboratories ($ABT) to $142.00 and $139.00, respectively.

Announcements· Aug 6

Texas Governor Abbott congratulates Oklo on achieving first criticality in under a year, marking a milestone in nuclear innovation and isotope production for medical therapies.
Governor Abbott praises Texas' leadership in nuclear development, citing advancements in workforce and domestic supply chains that will power innovation and strengthen the nation's future.
The achievement will help expand isotope production for critical medical therapies and reinforce Texas' leadership in nuclear innovation, according to Governor Abbott.

Controversies· Jul 29

Abbott Laboratories has been ordered to pay $495 million in damages and $400 million in punitive damages after a Missouri court found the company failed to warn that its Similac formula for premature infants increased the risk of necrotizing enterocolitis (NEC).
The company plans to appeal the verdict, which is the second jury to find against cow's milk baby formulas this year, with over 1,000 similar cases pending in US courts.
Abbott's shares fell 8% on the news, with the company's stock holding steady for now but potentially facing future legal trouble and reputational damage.

Macro· May 19

The post suggests that Abbott Laboratories is involved in a lithium refinery event that is being touted as beneficial for green energy.

Technical Analysis· Jan 22

$ABT is in a massive bull flag on the weekly chart, indicating a potential breakout.
The stock has formed an Adam and Eve bottom on the 1hr chart, suggesting a reversal in price action.
$ABT is showing strong reversal from $1.00 support, with price action suggesting continuation to $1.45 resistance.

Generated by AI

Community

Of the messages about ABT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	37.89%	38.59%	49.25%
Newcomers	100%	62.11%	61.41%	50.75%

Regulars· Jul 16

The company reported a 13.0% YoY increase in revenue to $12.59B, beating estimates, and a 4.0% YoY increase in adjusted EPS to $1.31, also beating estimates.
The medical devices segment saw a 9.0% YoY increase in revenue, while the diagnostics segment saw a 42.3% YoY increase, and the company reaffirmed its FY26 comparable sales growth guidance of 6.5% to 7.5%.
The company's dividend payout was increased for the 54th consecutive year, and it returned $2.1B to shareholders in Q2 2026 via dividends and share repurchases, with a quarterly dividend declared at $0.63 per share.

Newcomers· Sep 13

Newcomers are filtering dividend stocks by strict safety rules, with only 39 passing out of 134.
They are surprised by how many established companies with decades of dividend hikes have payout ratios above 60%, including Coca-Cola, Pepsi, and Johnson & Johnson.
Names like Caterpillar, Lowe's, Abbott, and Walmart are considered to be good companies with low payout ratios, making them attractive to newcomers.

Generated by AI

Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an HIV franchise that continues to gain momentum, while Abbott is offering considerably more diversification across medical devices, diagnostics, nutrition and established pharmaceuticals, as […]

2d agoYahoo Finance

Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note

Abbott (ABT) concluded the recent trading session at $101.07, signifying a -2.34% move from its prior day's close.

5d agoYahoo Finance

MOCA finally names new director after lengthy search, years of leadership turmoil

The Museum of Contemporary Art has appointed Jonathan Abbott, formerly of GBH in Boston, as its new chief executive and director. Abbot will be the institution's sixth leader since 2008.

5d agoLos Angeles Times

Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery

Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000. Information Technology was the main driver of […]

5d agoYahoo Finance

Also Discussed

Investors talking about ABT also mention

#	Name	Attention
1	AbbVie Inc.ABBV	0%-0.06
2	DexCom Inc.DXCM	0%0
3	ArcblockABT	0%new
4	Stryker CorporationSYK	0.01%+0.01
5	Metalpha Technology Holding LimitedMATH	0%new
6	Medtronic plcMDT	0%+0
7	Equity Bancshares Inc.EQBK	0%0
8	Becton, Dickinson and CompanyBDX	0%0
9	Johnson & JohnsonJNJ	0%-0.06
10	Danaher Corp.DHR	0.02%+0.02

Abbott Laboratories

Healthcare
Medical Devices

Abbott Laboratories is a global healthcare company that develops and markets a broad portfolio of medical devices, diagnostics, nutritional products, and branded generic medicines. Its current business is organized around four core segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. Abbott’s medical device portfolio includes technologies used in areas such as cardiovascular care, diabetes management, neuromodulation, and structural heart treatment, while its diagnostics business supplies testing systems and rapid assays used by hospitals, laboratories, and other care settings. The company’s nutrition products serve infants, children, and adults through clinically oriented formulas and everyday nutrition brands. Abbott Laboratories also sells branded generic medicines in international markets, supporting access to established therapies across multiple regions. Headquartered in Abbott Park, Illinois, Abbott plays a significant role in global healthcare by serving consumers, healthcare providers, and institutions across a wide range of clinical and everyday health needs.

Website

Location

100 Abbott Park Road

Abbott Park, IL, 60064-6400

United States

Social

What share of all stock conversation is about ABT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.03	0.01% +0.01	0.01% +0	0.01% -0.03

Sep 13

Abbott Laboratories (ABT) was among a list of 39 dividend stocks that passed four basic safety rules, including a 55% payout test, out of 134 filtered stocks.
Gov. Abbott of Texas has cracked down on data centers, requiring them to produce their own electricity and not pass costs to residential customers, citing concerns about past electricity outages in the state.
Abbott Laboratories is mentioned as a potential investment consideration, along with BYD, in a comment about buying stocks.

Generated by AI

Sentiment

Of the messages about ABT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +30.65	95.24% +5.04	84.07% -3.24
Bearish	—	0% -30.65	4.76% -5.04	15.93% +3.24

Bullish· Jul 16

Abbott Laboratories ($ABT) is expected to rally back above $100 in coming weeks, driven by a solid quarter with a medtech business inflection and more beat-and-raise quarters ahead.
The company's Q2 beat and raised guidance have led to a significant price increase, with $ABT up 11% on heavy volume, and the stock is expected to continue its upward momentum.
Analysts are optimistic about Abbott's prospects, with the company raising its FY26 adjusted EPS view to $5.45-$5.60, and projecting full-year 2026 comparable sales growth of 6.5% to 7.5%, exceeding consensus estimates.

Bearish· May 8

Abbott Laboratories is experiencing a decline in stock price, with some investors expecting it to hit $80 or for the market to shift away from the chip sector.
The company's lawsuits are a major concern, with some investors believing that relief will only come once they expire.
The stock's recent performance has been seen as a "classic fail" and a "value trap" by some investors, with some even calling it "cancerous" and "retarded".

Generated by AI

Topics

Of the messages about ABT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Macro	60%	3.13%	13.52%	28.32%
Technical Analysis	0%	71.79%	61.14%	6.12%
Announcements	20%	22.57%	17.33%	17.6%
Earnings	0%	0%	0%	6.02%
Analysts	0%	2.19%	7.81%	30.1%
Controversies	20%	0.31%	0.19%	11.84%

Earnings· Apr 16

Abbott Laboratories reported Q1 earnings of $1.15 per share, beating the FactSet Consensus of $1.14, and revenue of $11.16B, a 7.8% increase year-over-year.
The company cut its adjusted earnings per share guidance for FY26 to $5.38-$5.58, below consensus estimates, citing acquisition costs and margin pressure.
Abbott Laboratories' shares fell ~4% despite the earnings beat, as investors pointed to the acquisition of Exact Sciences as a drag on the company's performance and pressure on earnings.

Analysts· Jan 27

Morgan Stanley lowered its price target for Abbott Laboratories ($ABT) to $151.00 from $157.00.
Raymond James analysts maintain an Outperform rating for Abbott Laboratories ($ABT) with a lowered price target of $143.00.
Analysts at UBS Group and Credit Suisse Group have raised their price targets for Abbott Laboratories ($ABT) to $142.00 and $139.00, respectively.

Announcements· Aug 6

Texas Governor Abbott congratulates Oklo on achieving first criticality in under a year, marking a milestone in nuclear innovation and isotope production for medical therapies.
Governor Abbott praises Texas' leadership in nuclear development, citing advancements in workforce and domestic supply chains that will power innovation and strengthen the nation's future.
The achievement will help expand isotope production for critical medical therapies and reinforce Texas' leadership in nuclear innovation, according to Governor Abbott.

Controversies· Jul 29

Abbott Laboratories has been ordered to pay $495 million in damages and $400 million in punitive damages after a Missouri court found the company failed to warn that its Similac formula for premature infants increased the risk of necrotizing enterocolitis (NEC).
The company plans to appeal the verdict, which is the second jury to find against cow's milk baby formulas this year, with over 1,000 similar cases pending in US courts.
Abbott's shares fell 8% on the news, with the company's stock holding steady for now but potentially facing future legal trouble and reputational damage.

Macro· May 19

The post suggests that Abbott Laboratories is involved in a lithium refinery event that is being touted as beneficial for green energy.

Technical Analysis· Jan 22

$ABT is in a massive bull flag on the weekly chart, indicating a potential breakout.
The stock has formed an Adam and Eve bottom on the 1hr chart, suggesting a reversal in price action.
$ABT is showing strong reversal from $1.00 support, with price action suggesting continuation to $1.45 resistance.

Generated by AI

Community

Of the messages about ABT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	37.89%	38.59%	49.25%
Newcomers	100%	62.11%	61.41%	50.75%

Regulars· Jul 16

The company reported a 13.0% YoY increase in revenue to $12.59B, beating estimates, and a 4.0% YoY increase in adjusted EPS to $1.31, also beating estimates.
The medical devices segment saw a 9.0% YoY increase in revenue, while the diagnostics segment saw a 42.3% YoY increase, and the company reaffirmed its FY26 comparable sales growth guidance of 6.5% to 7.5%.
The company's dividend payout was increased for the 54th consecutive year, and it returned $2.1B to shareholders in Q2 2026 via dividends and share repurchases, with a quarterly dividend declared at $0.63 per share.

Newcomers· Sep 13

Newcomers are filtering dividend stocks by strict safety rules, with only 39 passing out of 134.
They are surprised by how many established companies with decades of dividend hikes have payout ratios above 60%, including Coca-Cola, Pepsi, and Johnson & Johnson.
Names like Caterpillar, Lowe's, Abbott, and Walmart are considered to be good companies with low payout ratios, making them attractive to newcomers.

Generated by AI

Abbott Laboratories

Social

Sep 13

Bullish· Jul 16

Bearish· May 8

Earnings· Apr 16

Analysts· Jan 27

Announcements· Aug 6

Controversies· Jul 29

Macro· May 19

Technical Analysis· Jan 22

Regulars· Jul 16

Newcomers· Sep 13

Abbott Moves Again To Slam The Brakes On Texas Data Center Growth

Texas diesel hits record $5.97 as Abbott disaster declaration rattles VLO, PSX pre-market

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note

MOCA finally names new director after lengthy search, years of leadership turmoil

Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery

Also Discussed

Abbott Laboratories

Company Information

Location

Abbott Moves Again To Slam The Brakes On Texas Data Center Growth

Texas diesel hits record $5.97 as Abbott disaster declaration rattles VLO, PSX pre-market

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note

MOCA finally names new director after lengthy search, years of leadership turmoil

Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery

Also Discussed

Social

Sep 13

Bullish· Jul 16

Bearish· May 8

Earnings· Apr 16

Analysts· Jan 27

Announcements· Aug 6

Controversies· Jul 29

Macro· May 19

Technical Analysis· Jan 22

Regulars· Jul 16

Newcomers· Sep 13